SAB Biotherapeutics Presents Positive SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference
(24/7 MARKET NEWS) – SAB Biotherapeutics (NASDAQ:SABS) stated, this morning, that it presented positive safety and efficacy data from Phase 1 and 2a clinical trials of its influenza immunotherapy, SAB-176 at the AVG conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Seattle, Wash.
SAB Biotherapeutics is trading at $0.99, up $0.12 (+13.79%), on 151K premarket shares traded.
Its 52-week range is $0.3657 to $2.4821. It made a big move up the chart on April 18th and that day’s high of $1.47 is the next key inflection point.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.